Literature DB >> 31468221

ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era.

Anita Mamtani1, Monica Morrow2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31468221      PMCID： PMC6939879          DOI： 10.1245/s10434-019-07769-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.

Authors:  Anita Mamtani; Emily C Zabor; Michelle Stempel; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2019-07-24       Impact factor: 5.344

Review 2.  Lobular breast carcinoma and its variants.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Semin Diagn Pathol       Date:  2010-02       Impact factor: 3.464

3.  American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns.

Authors:  Abigail S Caudle; Kelly K Hunt; Susan L Tucker; Karen Hoffman; Sarah M Gainer; Anthony Lucci; Henry M Kuerer; Funda Meric-Bernstam; Ruchita Shah; Gildy V Babiera; Aysegul A Sahin; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2012-07-31       Impact factor: 5.344

4.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.

Authors:  Armando E Giuliano; Karla Ballman; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Monica Morrow; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

5.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.